Transaction overview
The Equity Club acquired a 100% stake in Brexia Med, the holding company of CareHub, an Italian platform for ambulatory care centers, on April 24, 2026. The deal was valued at $50 million and was announced on the same day. This strategic move aims to support and accelerate the growth of CareHub's network across Italy.
Deal structure and financing
Details regarding the equity and debt split for this acquisition are not publicly disclosed. However, it is known that The Equity Club entered into a co-control agreement with Quadrivio Group, a key investor in Brexia Med since 2024. Mediobanca acted as both buy-side and sell-side advisor for the deal. CareHub’s founders—Gianluca Santoro, Alessandro Bartucci, and Valentina Rossi—are retaining their stake in the company while continuing to lead its operations.
No specific lock-up terms or IPO optionality are mentioned in the available information. Given that the acquisition is entirely financed by The Equity Club, any leverage metrics related to this transaction remain undisclosed.
Strategic context
The strategic rationale behind The Equity Club's investment in CareHub aligns with their broader objective of supporting and accelerating growth for Italian excellence companies. CareHub operates a network of ambulatory care centers across several regions in Italy, including Friuli-Venezia Giulia, Lombardy, Abruzzo, Umbria, and Tuscany. By acquiring the 100% stake in Poliambulatori San Gaetano, an established leader in ambulatory diagnostic services with operations primarily in Veneto, CareHub aims to integrate a highly innovative service offering into its network.
Quadrivio Group's existing investment underscores their belief in CareHub’s potential as a leading player in the longevity and healthcare segments. The Equity Club's entry will facilitate further consolidation within the sector by financing new acquisitions and strengthening CareHub’s position among independent operators in Italy.
Regulatory path
There is no public information available regarding specific regulatory scrutiny for this acquisition. Given that it involves Italian entities, it is likely that the transaction was reviewed under Italian competition law but did not require significant remedies or lengthy delays. The transaction size of $50 million suggests it might have been subject to mandatory filings in Italy but may not have necessitated extensive review by EU regulators due to its focus on regional operations within Italy.